{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:31:44Z","timestamp":1774611104990,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"German Society of Pediatric Nephrology"},{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>IgA vasculitis (IgAV) is the most common form of systemic vasculitis in childhood and frequently involves the kidney. A minority of patients with IgA vasculitis nephritis (IgAVN), especially those presenting with heavy proteinuria and\/or kidney failure at onset, are at risk of chronic end-stage kidney disease. For deciding upon treatment intensity, knowledge of the short-term clinical course of IgAVN is needed to improve treatment algorithms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>For this retrospective multicenter study, the medical records of 66 children with biopsy-proven IgAVN were reviewed. Age, gender, medical history and therapeutic interventions were recorded. Laboratory data included serum creatinine, albumin, urinary protein excretion (UPE) and glomerular filtration rate (eGFR). Threshold values were determined for each parameter, full remission was defined as no proteinuria and eGFR\u2009&gt;\u200990\u00a0ml\/min\/1.73m<jats:sup>2<\/jats:sup>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median age at onset of IgAVN was 8.9\u00a0years. 14.1% of the children presented with nephrotic syndrome, 50% had an eGFR below 90\u00a0ml\/min\/1.73 m<jats:sup>2<\/jats:sup> and 51.5% showed cellular crescents in renal histology. The treatment regimens varied notably. Forty-four patients were treated with immunosuppression; 17 patients with crescents or nephrotic syndrome were treated with corticosteroid (CS) pulse therapy. After 6\u00a0months, UPE had decreased from 3.7 to 0.3\u00a0g\/g creatinine and the proportion of patients with a decreased eGFR had fallen from 50.0% to 35.5%. Thirteen children (26.5%) achieved full remission within 6\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In most patients with IgAVN proteinuria decreases slowly and kidney function improves, but full remission is reached only in a minority after 6\u00a0months. Persistent heavy proteinuria in the first two months rarely developed into long-term proteinuria. Therefore, decisions for more intense treatment should take into account the course of UPE over time.<\/jats:p>\n                <jats:p>For a comparison of treatment effects, patient numbers were too small. Prospective, randomized controlled trials are necessary to clarify risk factors and the effect of immunosuppressive therapies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-022-03611-9","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T06:02:39Z","timestamp":1664863359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Early clinical course of biopsy-proven IgA vasculitis nephritis"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4812-9220","authenticated-orcid":false,"given":"Sarina","family":"Butzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imke","family":"Hennies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Gimpel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jutta","family":"Gellermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gesa","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja K.","family":"B\u00fcscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Lemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"3611_CR1","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(02)11279-7","volume":"360","author":"JMM Gardner-Medwin","year":"2002","unstructured":"Gardner-Medwin JMM, Dolezalova P, Cummins C, et al. Incidence of Henoch-Sch\u00f6nlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360:1197\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(02)11279-7.","journal-title":"Lancet"},{"key":"3611_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00467-014-2815-6","volume":"30","author":"M Pohl","year":"2015","unstructured":"Pohl M. Henoch-Sch\u00f6nlein purpura nephritis. Pediatr Nephrol. 2015;30:245\u201352. https:\/\/doi.org\/10.1007\/s00467-014-2815-6.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0140-6736(92)91341-5","volume":"339","author":"AR Goldstein","year":"1992","unstructured":"Goldstein AR, White RH, Akuse R, et al. Long-term follow-up of childhood Henoch-Sch\u00f6nlein nephritis. Lancet. 1992;339:280\u20132. https:\/\/doi.org\/10.1016\/0140-6736(92)91341-5.","journal-title":"Lancet"},{"key":"3611_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s004670050707","volume":"13","author":"K Sch\u00e4rer","year":"1999","unstructured":"Sch\u00e4rer K, Krmar R, Querfeld U, et al. Clinical outcome of Sch\u00f6nlein-Henoch purpura nephritis in children. Pediatr Nephrol. 1999;13:816\u201323. https:\/\/doi.org\/10.1007\/s004670050707.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/S0140-6736(02)09835-5","volume":"360","author":"J Ronkainen","year":"2002","unstructured":"Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch-Sch\u00f6nlein purpura: a retrospective cohort study. Lancet. 2002;360:666\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(02)09835-5.","journal-title":"Lancet"},{"key":"3611_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00005792-200109000-00001","volume":"80","author":"MC Calvi\u00f1o","year":"2001","unstructured":"Calvi\u00f1o MC, Llorca J, Garc\u00eda-Porr\u00faa C, et al. Henoch-Sch\u00f6nlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine (Baltimore). 2001;80:279\u201390. https:\/\/doi.org\/10.1097\/00005792-200109000-00001.","journal-title":"Medicine (Baltimore)"},{"key":"3611_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/00005792-199911000-00005","volume":"78","author":"FT Saulsbury","year":"1999","unstructured":"Saulsbury FT. Henoch-Sch\u00f6nlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore). 1999;78:395\u2013409. https:\/\/doi.org\/10.1097\/00005792-199911000-00005.","journal-title":"Medicine (Baltimore)"},{"key":"3611_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1067\/mpd.2000.103448","volume":"136","author":"BJ Foster","year":"2000","unstructured":"Foster BJ, Bernard C, Drummond KN, et al. Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr. 2000;136:370\u20135. https:\/\/doi.org\/10.1067\/mpd.2000.103448.","journal-title":"J Pediatr"},{"key":"3611_CR9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00467-010-1444-y","volume":"25","author":"S Edstr\u00f6m Halling","year":"2010","unstructured":"Edstr\u00f6m Halling S, S\u00f6derberg MP, Berg UB. Predictors of outcome in Henoch-Sch\u00f6nlein nephritis. Pediatr Nephrol. 2010;25:1101\u20138. https:\/\/doi.org\/10.1007\/s00467-010-1444-y.","journal-title":"Pediatr Nephrol"},{"issue":"Pt 2","key":"3611_CR10","first-page":"1089","volume":"1","author":"SR Meadow","year":"1973","unstructured":"Meadow SR, Glasgow EF, White RH, et al. Sch\u00f6nlein-Henoch nephritis. Perspect Nephrol Hypertens. 1973;1(Pt 2):1089\u2013104.","journal-title":"Perspect Nephrol Hypertens"},{"key":"3611_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/00365590903164480","volume":"43","author":"RF Andersen","year":"2009","unstructured":"Andersen RF, Rubak S, Jespersen B, et al. Early high-dose immunosuppression in Henoch-Sch\u00f6nlein nephrotic syndrome may improve outcome. Scand J Urol Nephrol. 2009;43:409\u201315. https:\/\/doi.org\/10.3109\/00365590903164480.","journal-title":"Scand J Urol Nephrol"},{"key":"3611_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/s0272-6386(99)70178-2","volume":"33","author":"M Hattori","year":"1999","unstructured":"Hattori M, Ito K, Konomoto T, et al. Plasmapheresis as the sole therapy for rapidly progressive Henoch-Sch\u00f6nlein purpura nephritis in children. Am J Kidney Dis. 1999;33:427\u201333. https:\/\/doi.org\/10.1016\/s0272-6386(99)70178-2.","journal-title":"Am J Kidney Dis"},{"key":"3611_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1542\/peds.111.4.785","volume":"111","author":"Y Kawasaki","year":"2003","unstructured":"Kawasaki Y, Suzuki J, Nozawa R, et al. Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch-Sch\u00f6nlein nephritis. Pediatrics. 2003;111:785\u20139. https:\/\/doi.org\/10.1542\/peds.111.4.785.","journal-title":"Pediatrics"},{"key":"3611_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s004670050446","volume":"12","author":"P Niaudet","year":"1998","unstructured":"Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Sch\u00f6nlein-Henoch purpura nephritis. Pediatr Nephrol. 1998;12:238\u201343. https:\/\/doi.org\/10.1007\/s004670050446.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00467-017-3794-1","volume":"33","author":"I Hennies","year":"2018","unstructured":"Hennies I, Gimpel C, Gellermann J, et al. Presentation of pediatric Henoch-Sch\u00f6nlein purpura nephritis changes with age and renal histology depends on biopsy timing. Pediatr Nephrol. 2018;33:277\u201386. https:\/\/doi.org\/10.1007\/s00467-017-3794-1.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629\u201337. https:\/\/doi.org\/10.1681\/ASN.2008030287.","journal-title":"J Am Soc Nephrol"},{"key":"3611_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.asn.0000103869.08096.4f","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157\u201363. https:\/\/doi.org\/10.1097\/01.asn.0000103869.08096.4f.","journal-title":"J Am Soc Nephrol"},{"key":"3611_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1159\/000226129","volume":"30","author":"J Cheng","year":"2009","unstructured":"Cheng J, Zhang X, Zhang W, et al. Efficacy and safety of glucocorticoids therapy for IgA nephropathy: a meta-analysis of randomized controlled trials. Am J Nephrol. 2009;30:315\u201322. https:\/\/doi.org\/10.1159\/000226129.","journal-title":"Am J Nephrol"},{"key":"3611_CR19","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015;373:2225\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1415463.","journal-title":"N Engl J Med"},{"key":"3611_CR20","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","volume":"98","author":"T Rauen","year":"2020","unstructured":"Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98:1044\u201352. https:\/\/doi.org\/10.1016\/j.kint.2020.04.046.","journal-title":"Kidney Int"},{"key":"3611_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12098-011-0519-5","volume":"79","author":"F Deng","year":"2012","unstructured":"Deng F, Lu L, Zhang Q, et al. Improved outcome of Henoch-Schonlein purpura nephritis by early intensive treatment. Indian J Pediatr. 2012;79:207\u201312. https:\/\/doi.org\/10.1007\/s12098-011-0519-5.","journal-title":"Indian J Pediatr"},{"key":"3611_CR22","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00467-011-1827-8","volume":"26","author":"H Wakaki","year":"2011","unstructured":"Wakaki H, Ishikura K, Hataya H, et al. Henoch-Sch\u00f6nlein purpura nephritis with nephrotic state in children: predictors of poor outcomes. Pediatr Nephrol. 2011;26:921\u20135. https:\/\/doi.org\/10.1007\/s00467-011-1827-8.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s004670050447","volume":"12","author":"K Iijima","year":"1998","unstructured":"Iijima K, Ito-Kariya S, Nakamura H, et al. Multiple combined therapy for severe Henoch-Sch\u00f6nlein nephritis in children. Pediatr Nephrol. 1998;12:244\u20138. https:\/\/doi.org\/10.1007\/s004670050447.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000046235","volume":"21","author":"JT Flynn","year":"2001","unstructured":"Flynn JT, Smoyer WE, Bunchman TE, et al. Treatment of Henoch-Sch\u00f6nlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol. 2001;21:128\u201333. https:\/\/doi.org\/10.1159\/000046235.","journal-title":"Am J Nephrol"},{"key":"3611_CR25","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/ndt\/gfg617","volume":"19","author":"Y Kawasaki","year":"2004","unstructured":"Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. Nephrol Dial Transplant. 2004;19:858\u201364. https:\/\/doi.org\/10.1093\/ndt\/gfg617.","journal-title":"Nephrol Dial Transplant"},{"key":"3611_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00467-010-1723-7","volume":"26","author":"JM Park","year":"2011","unstructured":"Park JM, Won SC, Shin JI, et al. Cyclosporin A therapy for Henoch-Sch\u00f6nlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol. 2011;26:411\u20137. https:\/\/doi.org\/10.1007\/s00467-010-1723-7.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR27","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00467-011-1919-5","volume":"26","author":"O Jauhola","year":"2011","unstructured":"Jauhola O, Ronkainen J, Autio-Harmainen H, et al. Cyclosporine A vs. methylprednisolone for Henoch-Sch\u00f6nlein nephritis: a randomized trial. Pediatr Nephrol. 2011;26:2159\u201366. https:\/\/doi.org\/10.1007\/s00467-011-1919-5.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00467-003-1245-7","volume":"18","author":"J Ronkainen","year":"2003","unstructured":"Ronkainen J, Autio-Harmainen H, Nuutinen M. Cyclosporin A for the treatment of severe Henoch-Sch\u00f6nlein glomerulonephritis. Pediatr Nephrol. 2003;18:1138\u201342. https:\/\/doi.org\/10.1007\/s00467-003-1245-7.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR29","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00467-011-2057-9","volume":"27","author":"Y Du","year":"2012","unstructured":"Du Y, Hou L, Zhao C, et al. Treatment of children with Henoch-Sch\u00f6nlein purpura nephritis with mycophenolate mofetil. Pediatr Nephrol. 2012;27:765\u201371. https:\/\/doi.org\/10.1007\/s00467-011-2057-9.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000341914","volume":"36","author":"P Ren","year":"2012","unstructured":"Ren P, Han F, Chen L, et al. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Sch\u00f6nlein purpura nephritis. Am J Nephrol. 2012;36:271\u20137. https:\/\/doi.org\/10.1159\/000341914.","journal-title":"Am J Nephrol"},{"key":"3611_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00467-010-1741-5","volume":"26","author":"T Ninchoji","year":"2011","unstructured":"Ninchoji T, Kaito H, Nozu K, et al. Treatment strategies for Henoch-Sch\u00f6nlein purpura nephritis by histological and clinical severity. Pediatr Nephrol. 2011;26:563\u20139. https:\/\/doi.org\/10.1007\/s00467-010-1741-5.","journal-title":"Pediatr Nephrol"},{"key":"3611_CR32","first-page":"551","volume":"51","author":"FS Altugan","year":"2009","unstructured":"Altugan FS, Ozen S, Aktay-Ayaz N, et al. Treatment of severe Henoch-Sch\u00f6nlein nephritis: justifying more immunosuppression. Turk J Pediatr. 2009;51:551\u20135.","journal-title":"Turk J Pediatr"},{"key":"3611_CR33","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/rheumatology\/kez041","volume":"58","author":"S Ozen","year":"2019","unstructured":"Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford). 2019;58:1607\u201316. https:\/\/doi.org\/10.1093\/rheumatology\/kez041.","journal-title":"Rheumatology (Oxford)"},{"key":"3611_CR34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00112-013-2896-5","volume":"161","author":"M Pohl","year":"2013","unstructured":"Pohl M, Dittrich K, Ehrich J, et al. Behandlung der Purpura-Sch\u00f6nlein-Henoch-Nephritis bei Kindern und Jugendlichen. Monatsschr Kinderheilkd. 2013;161:543\u201353. https:\/\/doi.org\/10.1007\/s00112-013-2896-5.","journal-title":"Monatsschr Kinderheilkd"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03611-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-022-03611-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03611-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T18:04:11Z","timestamp":1664906651000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-022-03611-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3611"],"URL":"https:\/\/doi.org\/10.1186\/s12887-022-03611-9","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"8 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of the Albert Ludwig\u2019s University of Freiburg, Germany. The data used in the study was pseudonymised before its use. Written consent has been obtained from all participants\/legal guardians. Access to the data was consented and included in the formal ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent for data analysis for publication has been obtained from all participants\/legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"570"}}